Last updated: October 26, 2026
Basaglar, Eli Lilly’s insulin glargine product, is a mature follow-on insulin facing sustained price compression, interchangeable insulin glargine competition, and declining commercial leverage as diabetes treatment shifts toward GLP-1 therapies. The product remains commercially significant, with annual sales around $1 billion, but its growth profile depends more on volume retention, payer access, and manufacturing efficiency than on price expansion.
Basaglar is marketed in the United States by Lilly and was developed with Boehringer Ingelheim. Its active ingredient is insulin glargine-yfgn, a long-acting basal insulin corresponding to Sanofi’s Lantus. Basaglar was approved through the FDA’s 505(b)(2) pathway rather than the modern biosimilar pathway because it was approved before insulin products transitioned into the Public Health Service Act biologics framework.[1]
What is Basaglar and how does it compete in the insulin market?
Basaglar is a once-daily long-acting insulin used to improve glycemic control in adults and pediatric patients with diabetes mellitus. It is available primarily as:
- Basaglar KwikPen, a prefilled disposable pen
- Basaglar 10 mL vial
- Insulin glargine-yfgn, the active ingredient designation used in FDA labeling
Basaglar competes in the basal insulin market against:
| Product |
Active ingredient |
Company |
Regulatory status |
Market position |
| Lantus |
Insulin glargine |
Sanofi |
Reference insulin |
Originator product |
| Basaglar |
Insulin glargine-yfgn |
Eli Lilly/Boehringer Ingelheim |
505(b)(2) follow-on insulin |
Major lower-priced Lantus competitor |
| Semglee |
Insulin glargine-yfgn |
Biocon Biologics/Viatris |
Biosimilar and interchangeable biosimilar to Lantus |
Direct interchangeable competitor |
| Rezvoglar |
Insulin glargine-aglr |
Eli Lilly |
Biosimilar and interchangeable biosimilar to Lantus |
Lilly’s second insulin glargine product |
| Toujeo |
Insulin glargine U-300 |
Sanofi |
Concentrated basal insulin |
Higher-concentration differentiated product |
| Tresiba |
Insulin degludec |
Novo Nordisk |
Long-acting basal insulin |
Competing non-glargine product |
Basaglar’s principal commercial advantage has been its lower price relative to Lantus, combined with broad payer coverage and established physician familiarity. Its principal weakness is that insulin glargine has become a highly commoditized category.
How much revenue does Basaglar generate?
Basaglar has developed into a roughly $1 billion annual product for Lilly. Lilly reports Basaglar revenue separately in its annual filings, although reported results are affected by foreign exchange, rebates, gross-to-net adjustments, and changes in channel mix.
| Fiscal year |
Approximate Lilly Basaglar revenue |
Financial direction |
| 2021 |
Approximately $1.0 billion |
Growth from broader adoption |
| 2022 |
Approximately $1.1 billion |
Continued volume expansion |
| 2023 |
Approximately $1.2 billion |
Higher demand, offset by pricing pressure |
| 2024 |
Approximately $1.1 billion |
Mature-market erosion and lower realized pricing |
Sources: Eli Lilly annual reports and Form 10-K filings for fiscal years 2021-2024.[2-5]
The trajectory shows three phases:
- Early expansion after U.S. launch, driven by conversion from Lantus and payer preference for lower-cost basal insulin.
- Stabilization near the $1 billion level as Basaglar achieved broad formulary access.
- Price and share pressure from interchangeable biosimilars, insulin affordability reforms, and competition from other basal insulin products.
Basaglar remains material to Lilly’s diabetes portfolio, but it is no longer a central growth driver. Lilly’s financial expansion is now concentrated in Mounjaro, Zepbound, Trulicity, Verzenio, Taltz, Jardiance, and related high-growth products.
When did Basaglar lose exclusivity and face generic or biosimilar competition?
Basaglar did not receive the same 12-year reference-product exclusivity associated with a conventional innovator biologic approved under a BLA. It was approved as a 505(b)(2) product, and its commercial protection was shaped primarily by Lantus patent litigation and settlement terms.
Key milestones include:
| Date |
Event |
| 2000 |
FDA approved Lantus, insulin glargine, for Sanofi |
| 2014 |
Sanofi sued Lilly over Lantus-related patents after Lilly sought approval for Basaglar |
| September 2015 |
Lilly and Sanofi settled the U.S. patent litigation |
| December 15, 2016 |
Basaglar launched in the United States under the settlement framework |
| 2015 |
Abasaglar, the European brand name for Basaglar, launched in certain European markets |
| July 2021 |
FDA approved Semglee as the first interchangeable biosimilar insulin product |
| December 2021 |
FDA approved Rezvoglar as an interchangeable biosimilar to Lantus |
| 2023 onward |
Interchangeable insulin glargine products expanded payer and pharmacy substitution pressure |
The relevant commercial event was not the expiration of a Basaglar patent. The market opened because Lilly negotiated a launch date after resolving Sanofi’s Lantus patent claims. The settlement allowed Basaglar to enter before the full commercial maturity of the Lantus franchise while reducing immediate litigation risk.[6]
What is the Orange Book status of Basaglar?
Basaglar was approved under NDA 205692 through the 505(b)(2) pathway. Its regulatory history is associated with insulin glargine-yfgn rather than with a traditional BLA reference-product framework.[1]
The Orange Book is relevant because Basaglar was approved as an NDA product. However, its competitive position is not defined by a dense, long-duration patent estate comparable to many small-molecule specialty drugs. The primary patent dispute concerned Sanofi’s Lantus patents, not a broad portfolio of Basaglar formulation or delivery patents.
The commercial implications are:
- Basaglar has limited ability to block competing insulin glargine products through product-specific patent litigation.
- Interchangeable biosimilar products can compete directly with Basaglar even though their legal reference product is Lantus.
- Pharmacy substitution and payer formulary design can shift basal insulin volume rapidly.
- The pen device, manufacturing process, and presentation may create practical barriers, but they do not provide the same protection as a strong composition-of-matter patent.
Which companies are challenging Basaglar in the market?
Basaglar faces competition from Sanofi, Viatris and Biocon, and Lilly’s own Rezvoglar product.
Semglee
Semglee is marketed by Viatris and Biocon Biologics. It was the first insulin product designated interchangeable with Lantus under the biosimilar pathway. The interchangeable designation increases substitution potential at the pharmacy level, subject to state law and payer policy.[7]
Semglee’s launch created direct pricing pressure on Basaglar because it competed in the same insulin glargine category while carrying an interchangeability designation that Basaglar does not have.
Rezvoglar
Rezvoglar is Lilly’s interchangeable biosimilar insulin glargine product. It creates an unusual internal competition dynamic: Lilly sells both Basaglar and Rezvoglar in the same broad therapeutic class.
The products differ in regulatory route and commercial positioning:
| Attribute |
Basaglar |
Rezvoglar |
| Active ingredient |
Insulin glargine-yfgn |
Insulin glargine-aglr |
| Approval pathway |
505(b)(2) |
Biosimilar pathway |
| Interchangeable designation |
No |
Yes |
| Reference product |
Lantus-related follow-on framework |
Lantus |
| Strategic role |
Established basal insulin franchise |
Lower-cost interchangeable product |
| Cannibalization risk |
High from internal and external substitution |
Potentially captures price-sensitive volume |
Lilly can use portfolio segmentation to preserve access across different formularies, but the two products also risk shifting Lilly volume from a higher-priced brand to a lower-priced alternative.
What formulations and delivery systems are protected?
Basaglar is sold in a prefilled pen and vial presentations. The KwikPen delivery system improves convenience and supports adherence, but the pen is not a substantial barrier to competition by itself.
The principal commercial protections are practical rather than patent-driven:
- Device manufacturing capability
- Sterile fill-finish capacity
- Consistent insulin aggregation and stability control
- Cartridge and pen component supply
- Device usability and human-factors compliance
- Payer contracts and formulary placement
- Physician and patient familiarity
Insulin products require complex manufacturing and quality control. The active ingredient is not difficult to describe chemically, but production requires recombinant expression, purification, formulation, aseptic filling, and validated analytical testing. These requirements make market entry more difficult than ordinary oral generics, even when formal patent protection is weak.
How strong is the Basaglar patent estate?
Basaglar has a moderate-to-weak blocking patent position compared with innovative specialty medicines.
Patent strengths
- Established manufacturing know-how
- Device and presentation experience
- Regulatory history and clinical familiarity
- Scale advantages in insulin production
- Commercial contracts with pharmacy benefit managers
- Brand recognition among prescribers and patients
Patent weaknesses
- No broad composition-of-matter exclusivity around insulin glargine
- No 12-year biologic reference-product exclusivity
- Direct exposure to interchangeable biosimilar products
- Limited ability to prevent competitors from marketing insulin glargine through product-specific patents
- Strong payer leverage against mature basal insulin products
The key barrier is manufacturing execution, not a long-lived patent moat. This distinction matters for investors and potential licensors. A competitor with sufficient biologics manufacturing capacity and payer access can enter without replicating every aspect of Lilly’s commercial infrastructure.
What is Basaglar’s FDA regulatory status?
Basaglar remains FDA-approved for glycemic control in adults and children with diabetes mellitus. It is not an interchangeable biosimilar to Lantus.
The distinction between Basaglar and newer products is important:
- Basaglar is a 505(b)(2) follow-on insulin.
- Semglee and Rezvoglar were approved under the biosimilar framework.
- Semglee and Rezvoglar received interchangeable designations.
- Basaglar can be prescribed and dispensed as an insulin glargine product, but it does not carry the same automatic-substitution position as an interchangeable biosimilar.
The FDA’s transition of insulin products from the drug framework to the biologics framework took effect in March 2020. The transition increased the importance of the biosimilar pathway for subsequent insulin products and clarified the legal framework for competing insulin glargine products.[8]
What pricing changes affect Basaglar revenue?
U.S. insulin pricing has shifted from list-price expansion to affordability programs and net-price management.
Lilly reduced the list price of Basaglar KwikPen and introduced a $35 monthly insulin cap for eligible patients. The company announced a reduction in the list price of Basaglar to $92 per five-pen package, effective January 1, 2024, alongside comparable affordability measures for other Lilly insulin products.[9]
These measures have competing effects:
- They improve access and reduce patient abandonment.
- They weaken gross sales growth based on price increases.
- They increase the importance of volume and formulary positioning.
- They may reduce gross-to-net variability for some patients while increasing rebate and discount pressure in commercial channels.
- They make list-price comparisons less useful than net sales and payer-specific economics.
The federal Medicare insulin cost-sharing cap also changed the category’s economics. Under the Inflation Reduction Act, covered insulin products are subject to a $35 monthly cost-sharing limit for Medicare beneficiaries beginning in phases during 2023 and 2024.[10]
What generic launch risks exist for Basaglar?
Basaglar does not face a conventional generic launch event with a single date and immediate substitution across all payers. Its competitive erosion is gradual and channel-specific.
The main risks are:
Interchangeable biosimilar substitution
Semglee and Rezvoglar can be substituted under applicable state pharmacy laws and payer rules. Their interchangeable status gives them a stronger mechanism for automatic substitution than Basaglar has.
Formulary exclusion
Pharmacy benefit managers can exclude Basaglar, Lantus, Semglee, or Rezvoglar in favor of a preferred product. Contract cycles can move large prescription volumes without a major clinical change.
Internal Lilly cannibalization
Rezvoglar may protect Lilly’s insulin glargine franchise but also shift demand away from Basaglar. This can preserve company-level revenue while lowering the average revenue per unit.
Basal insulin category compression
GLP-1 receptor agonists and dual incretin therapies can reduce insulin initiation or delay escalation for some patients with type 2 diabetes. The effect is more limited in type 1 diabetes and in patients with advanced insulin dependence, but it still changes the growth outlook for basal insulin.
Government price pressure
Medicare negotiation does not directly establish a negotiated price for Basaglar under the first negotiation cycle, but broader federal affordability policy affects insulin pricing, patient cost sharing, and payer bargaining behavior.
How does Basaglar compare with Lantus, Semglee, and Rezvoglar?
| Factor |
Basaglar |
Lantus |
Semglee |
Rezvoglar |
| Brand type |
Follow-on insulin |
Originator |
Biosimilar |
Biosimilar |
| FDA pathway |
505(b)(2) |
Original NDA |
Biosimilar |
Biosimilar |
| Interchangeable |
No |
Reference product |
Yes |
Yes |
| Main commercial advantage |
Scale and established access |
Physician familiarity and legacy share |
Substitution potential |
Lilly distribution and interchangeability |
| Main weakness |
Price erosion |
Higher legacy pricing |
Payer and manufacturing execution |
Internal cannibalization |
| Patent moat |
Limited |
Mature and largely eroded |
Limited |
Limited |
| Long-term outlook |
Mature, pressured |
Declining share but durable base |
Share-gain opportunity |
Share-gain opportunity |
Basaglar’s most important advantage is not regulatory exclusivity. It is its installed commercial base. Its most important threat is the combination of interchangeable competition and Lilly’s own lower-cost portfolio strategy.
What licensing and partnership arrangements support Basaglar?
Basaglar was developed through the Lilly-Boehringer Ingelheim alliance covering diabetes medicines. The companies have collaborated on discovery, development, regulatory approval, and commercialization of several diabetes products, including insulin products and oral diabetes therapies.[11]
The alliance gives Basaglar access to:
- Lilly’s U.S. commercial infrastructure
- Boehringer Ingelheim’s development and manufacturing capabilities
- Shared diabetes research and regulatory resources
- Broader payer and medical-affairs coverage
The principal strategic issue is portfolio coordination. Lilly must balance Basaglar, Rezvoglar, Humalog, other insulin products, and non-insulin diabetes therapies while managing the migration of investment toward higher-growth medicines.
What is the outlook for Basaglar revenue and market share?
Basaglar is likely to remain a large but declining or flat-to-low-growth product in nominal revenue terms. A sharp collapse is less likely because insulin glargine remains a standard basal insulin and many patients require long-term insulin therapy.
The most likely trajectory is:
| Period |
Expected commercial pattern |
| Near term |
Continued price pressure, stable underlying demand, aggressive formulary competition |
| Medium term |
Share transfer to interchangeable biosimilars and possible migration to Rezvoglar |
| Longer term |
Mature basal insulin erosion, partially offset by diabetes prevalence and continued insulin dependence |
Basaglar revenue will depend on four variables:
- Net price after rebates and affordability discounts.
- Lilly’s preferred formulary status.
- The rate of substitution to Semglee and Rezvoglar.
- The extent to which GLP-1 and dual incretin therapies alter basal insulin use.
The product remains economically relevant because even a mature insulin franchise can generate substantial cash flow at scale. Its strategic value is less about future growth and more about maintaining payer relationships, diabetes portfolio breadth, manufacturing utilization, and patient access.
Key Takeaways
- Basaglar is a mature follow-on insulin glargine product marketed by Eli Lilly and developed with Boehringer Ingelheim.
- Annual Lilly revenue has remained around $1 billion, but price compression is limiting growth.
- Basaglar was approved through the 505(b)(2) pathway and is not an interchangeable biosimilar.
- Semglee and Rezvoglar create direct interchangeable competition in insulin glargine.
- Lilly’s Rezvoglar can protect the company’s category share while cannibalizing Basaglar.
- The product has limited patent-based protection; manufacturing scale, payer access, and brand familiarity are more important barriers.
- U.S. insulin affordability policies and the $35 Medicare cost-sharing cap are reducing pricing power.
- Basaglar is likely to remain commercially durable but strategically secondary to Lilly’s incretin and oncology growth products.
FAQs
Is Basaglar a biosimilar to Lantus?
Basaglar is a follow-on insulin approved through the 505(b)(2) pathway. It is not designated as an interchangeable biosimilar to Lantus.
Can a pharmacy automatically substitute Semglee or Rezvoglar for Basaglar?
Automatic substitution depends on state pharmacy law, payer rules, and the specific prescription. Semglee and Rezvoglar have interchangeable biosimilar designations to Lantus, but that designation does not automatically make them interchangeable with Basaglar in every jurisdiction.
Does Basaglar have patent protection through 2030?
Basaglar does not have a widely recognized long-duration composition patent that blocks insulin glargine competition through 2030. Its market position is based primarily on regulatory approval, manufacturing, commercial scale, and payer access.
Is Basaglar cheaper than Lantus?
Basaglar has generally been positioned as a lower-priced alternative to Lantus. Actual patient cost depends on insurance coverage, rebates, pharmacy benefit design, eligibility for savings programs, and federal or commercial cost-sharing limits.
Will GLP-1 drugs eliminate the market for Basaglar?
No. GLP-1 receptor agonists and dual incretin therapies may reduce insulin initiation or intensification for some patients with type 2 diabetes, but insulin remains essential for type 1 diabetes and continues to be required by many patients with advanced type 2 diabetes.
References
- U.S. Food and Drug Administration. (2015). FDA approves Basaglar, the first “follow-on” insulin glargine product. https://www.fda.gov
- Eli Lilly and Company. (2022). 2021 annual report.
- Eli Lilly and Company. (2023). 2022 annual report.
- Eli Lilly and Company. (2024). 2023 annual report.
- Eli Lilly and Company. (2025). 2024 annual report.
- Sanofi. (2015). Sanofi and Eli Lilly resolve insulin glargine patent litigation.
- U.S. Food and Drug Administration. (2021). FDA approves first interchangeable biosimilar insulin product. https://www.fda.gov
- U.S. Food and Drug Administration. (2020). Transition provisions for insulin and other biological products. https://www.fda.gov
- Eli Lilly and Company. (2023). Lilly announces lower list prices and $35 monthly insulin cap for eligible patients.
- Centers for Medicare & Medicaid Services. (2023). Medicare insulin cost-sharing provisions under the Inflation Reduction Act. https://www.cms.gov
- Eli Lilly and Company. (2024). Lilly-Boehringer Ingelheim diabetes alliance information.
